Source comparison
Scenesse Same as Melanotan-1: Side Effect and Safety Profile Comparison
Regulatory Status FDA-approved, EMA-approved for EPP treatment Not FDA-approved; distributed as research chemical Scenesse has post-market surveillance; Melanotan-1 does not Manufacturing Oversight cGMP facilities with batch release testing Variable; no mandat
This comparison does not assign a generated winner or score.
- Regulatory Status
- FDA-approved, EMA-approved for EPP treatment
- Not FDA-approved; distributed as research chemical
- Scenesse has post-market surveillance; Melanotan-1 does not
- Manufacturing Oversight
- cGMP facilities with batch release testing
- Variable; no mandated quality standards
- Purity and sterility guaranteed vs supplier-dependent
- Common Side Effects
- Nausea (31%), headache, injection site darkening
- Nausea (40–50%), facial flushing, spontaneous erections
- Both share MC1R-mediated effects; Melanotan-1 anecdotal rates
- Dosing Protocol
- 16mg controlled-release implant every 60 days
- 0.5–1mg daily injections (anecdotal, not standardized)
- Scenesse offers consistent plasma levels; injections cause peaks/troughs
- Clinical Trial Data
- Phase III trials with 1,500+ patient-years
- No Phase III data; case reports and user forums only
- Evidence base differs by orders of magnitude
- Professional Assessment
- Use restricted to EPP diagnosis under dermatologist supervision
- Off-label use carries risk of contamination, dosing errors, and unknown long-term safety profile